OVERVIEW

10th Annual Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting is organized by Practical Recommendations in Immuno and Molecular Oncology (PRIMO) and will be held from Feb 05 - 08, 2025 at ‘Alohilani Resort Waikiki Beach, Honolulu, Hawaii, United States of America.

Description:
PRIMO is a unique opportunity to receive CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

Learning Objectives:

  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care.

What is PRIMO?
The annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and highlight anticipated advances for the coming year. This will be accomplished through plenary presentations, case studies, and panel discussions.

The meeting will educate attendees on the latest advances for the treatment of solid tumors and hematologic malignancies. It will also foster discussions about incorporating innovative agents into treatment decisions for patients with advanced cancers while practicing in the new value-based environment.

As the science of oncology continues to advance at a pace never seen before in history, the PRIMO meeting provides attendees with practical recommendations on how to integrate these new data into their everyday practice. From biomarker testing and the implementation of NexGen Sequencing (NGS), to targeted and immunotherapy adoption, to sequencing and/or combining agents, to managing patient expectations and side effects, PRIMO will provide attendees with the tools and strategies needed to implement and optimize therapy.

The meeting Co-Chairs, Dr. Hope S. Rugo and Dr. Julie Vose, along with an expert Steering Committee, are currently assembling a stellar faculty for the 2025 annual PRIMO Meeting.

The PRIMO Meeting agenda is tailored to meet the educational needs of all attendees, with an emphasis on the following key areas:

  • Practical considerations of applying biomarkers and targeted therapy in clinical decision making
  • Integration of emerging immunotherapy and targeted therapy, with a focus on novel management approaches, into daily practice
  • Patient selection, as well as timing and sequencing of therapy
  • Management of toxicities of the newer and novel therapies with a view to improving patient outcomes
  • The role of current trends in oncology, including the use of big data and the increased focus on value in cancer care

Educational Objectives:
After completing this activity, the participant should be better able to:

  • Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
  • Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
  • Identify patients who are appropriate candidates for targeted and immunologic therapies;
  • Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
  • Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

The Practical Recommendations in Immuno and Molecular Oncology Meeting is a unique opportunity to receive CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

KEY DATES

Event Start Date
05 Feb, 2025
Event Start Date
Event End Date
08 Feb, 2025
Event End Date
Credits

Accreditation and Credit Statements
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 12.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician
The Medical Educator Consortium designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”

Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)

Nursing
The Medical Educator Consortium designates this activity for 12.00 contact hours.

ILNA Coding:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:

  • Care Continuum (OCN, CBCN, CPHON, A0CNP): 12.0 points
  • Care of the Pediatric Hematology and Oncology Patient (CPHON): 1.5 points*
  • Cellular Collection, Preparative Regimens, and Infusion (BMTCN): 1.5 points*
  • Coordination of Care (CBCN): 2.5 points*
  • Diagnosis and Staging (CBCN): 2.5 points*
  • Early Post-Transplant Management and Education (BMTCN): 1.5 points*
  • Foundations of Transplant (BMTCN): 1.5 points*
  • Late Post-Transplant Management and Education (BMTCN) 1.5 points*
  • Nursing Practice (CBCN): 2.5 points*
  • Oncologic Emergencies (OCN, CPHON, AOCNP): 8.5 points*
  • Oncology Nursing Practice (OCN): 12.0 points*
  • Professional Practice/Performance (BMTCN, AOCNP): 8.5 point*
  • Roles of the APRN (AOCNP): 5.5 point*
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP): 8.5 points*
  • Transplant Process and Infusion (BMTCN): 1.5 points*
  • Treatment (OCN, CBCN, AOCNP, CPHON): 8.5 points

Total Points: 12.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated is the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of Nursing Continuing Professional Development (NCPD) awarded from this course and may only apply to the credential each nurse is renewing.

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD Accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Pharmacist
This Application-based activity has been approved for 12.00 contact hours (1.20 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is  JA4008179-0000-25-001-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Associate
The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

  • 12 AMA PRA Category 1 Credits™
  • 12 IPCE
  • 12 MOC
  • 12 Contact Hours
  • 1.2 CEUs
  • TARGET AUDIENCE

    PhysicianNursingPharmacistPhysician AssistantOncologistsHealthcare ProfessionalsResidentsNursesAllied Health ProfessionalsNurse PractitionersFellowsOther Health ProfessionalsImmunologistsMedical Practitioners

    SPECIALITIES

    OncologyAllergy and ImmunologyMolecular Biology

    SUGGESTED HOTELS

    CONFERENCE VENUE

    Location‘Alohilani Resort Waikiki Beach
    2490 Kalākaua Ave

    CANCELLATION & REFUND POLICY

    Refund Policy Should your schedule change and you cannot attend the event, please notify a PRIMO contact as soon as possible. Refund for advanced cancelation maybe made up until 30 days of the meeting start date, minus $100 processing fee. No refunds will be given within 30 days of the meeting.

    RELATED CONFERENCES & LIVE WEBINARS

    Oct 26 - 27, 2026 | Paris, ...

    Molecular Biology
    More actions
    FR€350

    Feb 01 - 02, 2027 | Dubai, Dubai, UAE

    Oncology
    30 CME
    ...
    More actions
    GB£19

    Feb 01 - 02, 2027 | Dubai, Dubai, UAE

    Pathology
    30 CME
    ...
    More actions
    GB£45